Today's Trend
Olema Pharmaceuticals, Inc. (OLMA) is trading higher today on heavy analyst activity and fresh catalysts. Investors are reacting to multiple bullish price‑target revisions and EPS estimate upgrades (HC Wainwright, JPMorgan, Jefferies, Citigroup), a recent better‑than‑expected quarterly report, and upcoming preclinical data presentations — offset by some bearish notes (Guggenheim) and a Goldman Sachs cut to its target. Volume is elevated, reflecting the tug‑of‑war between positive analyst initiation/raises and selective downside calls.
- Jefferies initiated coverage with a "Buy" and $40 price target (large upside vs. current levels), giving fresh institutional endorsement that can attract buyers. Jefferies Initiates Coverage - Benzinga
- JPMorgan raised its price target to $58 and kept an "Overweight" stance — a high-profile upward revision that can drive momentum and re-rate expectations. JPMorgan Raises Price Target - Benzinga
- HC Wainwright lifted EPS estimates across 2026–2030 and reiterated a "Buy" with a $38 target, signaling analyst confidence in improving fundamentals over the medium term. HC Wainwright Estimate Raises - MarketBeat
- Olema reported better‑than‑expected quarterly results this week, which, along with raised analyst outlooks, is a near‑term bullish catalyst supporting the stock. Earnings Beat Drives Stock - AmericanBankingNews
- Upcoming/preclinical data (palazestrant and OP‑3136) to be presented at AACR and a large reported $68.7M investor bet on a 2027 breast‑cancer launch are potential medium‑term catalysts for upside if data or investor interest validates the story. AACR Presentation - BusinessInsider Large Bet Report - The Globe and Mail
- Zacks notes the stock has been heavily sold (down ~33% over 4 weeks) and is technically oversold; that increases the chance of a short‑term bounce but also underscores elevated downside risk if catalysts disappoint. Oversold / Technical Note - Zacks
- Guggenheim published a pessimistic forecast and an analyst downgrade hit headlines, pressuring the stock intraday — a reminder that not all desks are aligned with the recent bullish notes. Guggenheim Pessimistic Forecast - AmericanBankingNews
- AmericanBankingNews reported an analyst downgrade that coincided with a notable intra‑day pullback, illustrating how mixed analyst views are fueling volatility. Analyst Downgrade / Price Reaction - AmericanBankingNews
- Goldman Sachs trimmed its price target from $38 to $27 (while keeping a "Buy"), which reduces the consensus upside and may cap near‑term rallies until data or execution de‑risk the story. Goldman Lowers Target - Benzinga